At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 85 enrolled
Drug / intervention
tipranavir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open Label, Clinical Trial to Evaluate Three Doses of Tipranavir Boosted With Ritonavir (500 mg/200 mg qd, 250 mg/100 mg Bid and 500 mg/100 mg Bid) by Assessing the Steady-state Pharmacokinetics and Short-term Efficacy and Safety in HIV-1 Positive Treatment naïve Patients
In Brief
A Phase 2 clinical trial evaluating tipranavir and ritonavir for HIV Infections. Completed, enrolled 85 participants across 12 sites in 3 countries.
Detailed Summary
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the steady-state pharmacokinetics and short-term efficacy and safety
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesGermany, Italy, Spain
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2007
Enrollment StartOct 2007
Primary CompletionMay 2008
TodayJul 2026
First PostedSep 18, 2007
Enrollment StartOct 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.8 years ago
Interventions
tipranavirdrug
ritonavirdrug